<DOC>
	<DOC>NCT00189774</DOC>
	<brief_summary>The purpose of this study is to investigate the superiority of nateglinide over placebo for inadequately controlled type 2 diabetic patients with pioglitazone treatment.</brief_summary>
	<brief_title>Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Nateglinide</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Type 2 diabetes mellitus under the treatment with pioglitazone Patients who cannot follow the diet therapy and/or exercise therapy Type 1 diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>nateglinide</keyword>
	<keyword>pioglitazone</keyword>
	<keyword>combination drug therapy</keyword>
	<keyword>treatment</keyword>
</DOC>